Mitochondrial / energy research
MOTS-c vs Elamipretide
MOTS-c therapeutic administration remains largely preclinical; elamipretide has extensive human development and a specific FDA-approved Barth-syndrome.
At a glance
MOTS-c
Elamipretide
Human evidence
Human studies show endogenous MOTS-c biology during exercise, and a genuine randomized Phase 2a trial of administered subcutaneous MOTS-c is recruiting in adults with prediabetes and overweight/obesity; no efficacy results are posted yet.
Elamipretide has multiple human trials. In primary mitochondrial myopathy, small early studies showed signals but the 218-person Phase III MMPOWER-3 trial missed both co-primary endpoints. Barth syndrome follows a separate rare-disease evidence and regulatory pathway and should not be generalized to wellness use.
Research focus
Metabolism, exercise physiology, ageing biology
Mitochondrial disease; Barth syndrome; broader mitochondrial research
Regulatory status
Not FDA-approved; FDA highlights absence of human drug-product exposure data.
Forzinity (elamipretide) received FDA accelerated approval for Barth syndrome patients ≥30 kg; this does not make generic SS-31 vials approved.
Route / formulation
Endogenous exercise-induced MOTS-c measurements are not evidence that injected MOTS-c is effective or safe.
Generic SS31 research products are not equivalent to Forzinity and may differ in quality/formulation.
No head-to-head human trial identified MOTS-c therapeutic administration remains largely preclinical; elamipretide has extensive human development and a specific FDA-approved Barth-syndrome product/indication.